United States · FDA National Drug Code directory
Soliqua 100/33
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0024-5761_dd3cca75-32f2-4e6d-8121-20f47e101495
- Product NDC
- 0024-5761
- Form
- INJECTION, SOLUTION
- Composition / generic term
- insulin glargine and lixisenatide
- Labeler
- Sanofi-Aventis U.S. LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20161121
- Source listing expiry
- 20271231
Source-listed ingredients
- INSULIN GLARGINE — 100 U/mL
- LIXISENATIDE — 33 ug/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE in 1 CARTON (0024-5761-01) / 3 mL in 1 SYRINGE · 0024-5761-01
- 5 SYRINGE in 1 CARTON (0024-5761-05) / 3 mL in 1 SYRINGE (0024-5761-02) · 0024-5761-05
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →